Skip to content

    Recently Viewed


      A photo of a pharmacist holding a bottle of medicine

      Janssen Pharmaceuticals releases a 2016 U.S. Transparency Report

      Jennifer Taubert, Company Group Chairman, Pharmaceuticals, The Americas, explains why Janssen is sharing information around its medication pricing and other business practices.

      Share Article
      share to

      Johnson & Johnson has a legacy of leadership when it comes to transparency. And the Janssen Pharmaceutical Companies of Johnson & Johnson recognize that consumers in the U.S. are particularly concerned about the high cost of healthcare these days. That’s why the company just released a 2016 U.S. Transparency Report that includes information on pricing and other business practices, covering everything from discovery to the commercialization of pharmaceuticals.

      “Our hope is that this report will address questions people may have, and that it will lead to more discussion about how we can work together to move toward a more value-based healthcare system—one that delivers what we all want: greater access to care at a more manageable cost, and, most importantly, better health for us all,” says Jennifer Taubert, Company Group Chairman, Pharmaceuticals, The Americas.

      Watch this video of Taubert to learn more about the 2016 U.S. Transparency Report and how it can help better inform consumers.

      2016 U.S. Transparency Report Jennifer Taubert

      More from Johnson & Johnson

      A female scientist conducting research in a laboratory, focusing on orphan drugs for rare diseases

      What is an orphan drug?

      The need for these rare disease therapies is strong, and access to them can be lifesaving. Here’s how Johnson & Johnson is innovating to help give patients options.
      Caring & giving
      Sam Seavey piloting an aircraft from the cockpit

      3 health advocates; 1 Johnson & Johnson program that offers empowerment and connection

      In the quest to solve the toughest health challenges, innovating therapies and finding treatments are essential—but so is supporting the patients living with these diseases. That’s exactly why Johnson & Johnson launched HealtheVoices a decade ago.
      Two cardiac electrophysiologists performing a cardiac ablation procedure to treat AFib

      What is cardiac ablation?

      For American Heart Month, learn how Johnson & Johnson is innovating to help treat the millions of people who are living with atrial fibrillation and other conditions that cause an irregular heartbeat.
      You are now leaving The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.